Document:

Form of Warrant

 Exhibit 4.1 
  

THE WARRANT AND THE SHARES OF COMMON STOCK REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER OR HYPOTHECATION IS IN
COMPLIANCE THEREWITH. 
  
 XENOGEN CORPORATION 
  
 WARRANT TO PURCHASE
             SHARES 
 OF COMMON STOCK 
  
 Warrant No. W-     
  
 THIS CERTIFIES THAT, for value received,
                     and its assigns are entitled to subscribe for and purchase
                     shares (as adjusted pursuant to Section 4 hereof, the “Shares”) of the fully paid and nonassessable
common stock, par value $0.001 per share (“Common Stock”), of Xenogen Corporation, a Delaware corporation (the “Company”), at the price of $3.29 per share (such price and such other price as shall result, from time
to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions set forth herein and in the Securities Purchase Agreement, dated
as of even date herewith, by and among the Company and the initial holder of this Warrant (the “Securities Purchase Agreement”). As used herein, the term “Date of Grant” means August 15, 2005. As used herein, the
term “Warrant” shall be deemed to include any warrants issued in exchange or upon transfer or partial exercise of this Warrant unless the context clearly requires otherwise. 
  
 1. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at any
time and from time to time from the six-month anniversary of the Date of Grant through August 15, 2010. 
  
 2. Method of Exercise; Payment; Issuance of New Warrant. 
  
 (a) Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in
whole or in part and from time to time, at the election of the holder hereof, by (x) the surrender of this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the
principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account designated by the Company (“Wire Transfer”) of an amount equal to the then applicable Warrant Price
multiplied by the number of Shares then being purchased or (y) if in connection with a registered public offering of the Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2
duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably satisfactory to the Company for payment to the Company either by certified or bank 

 
check or by Wire Transfer from the proceeds of the sale of shares to be sold by the holder in such public offering of an amount equal to the then applicable
Warrant Price per share multiplied by the number of Shares then being purchased. The person or persons in whose name(s) any certificate(s) representing the Shares shall be issuable upon exercise of this Warrant shall be deemed to have become the
holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the Shares represented thereby (and such Shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which
this Warrant is exercised. As soon as practicable after the exercise of this Warrant and in any event within three trading days thereafter, upon the terms and subject to the conditions of this Warrant, the Company at its expense will cause to be
issued in the name of and delivered to the holder, or as the holder may direct to a broker or other persons, a certificate or certificates for the number of Shares to which the holder shall be entitled on such exercise, in such denominations as may
be requested by the holder. In lieu of delivering physical certificates for the Shares issuable upon any exercise of this Warrant, provided the Company’s transfer agent is participating in the Depository Trust Company (“DTC”) Fast
Automated Securities Transfer (“FAST”) program, and that any legend upon the certificates for the Shares shall have been removed pursuant to Section 7 below, upon request of the holder, the Company shall use commercially reasonable efforts
to cause its transfer agent electronically to transmit such Shares by crediting the account of the holder’s broker with DTC through its Deposit Withdrawal Agent Commission system (provided that the same time limitations herein as for stock
certificates shall apply). 
  
 (b) On and after the Required
Effective Date of the Registration Statement (as defined in the Securities Purchase Agreement) through the Term of this Warrant, at any time that the Registration Statement or a successor registration statement is not effective, in lieu of
exercising this Warrant for cash, the holder may elect to receive shares equal to the value of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with notice of such
election substantially in the form attached hereto as Exhibit A-1 duly completed and executed (“Net Exercise”). The Company shall issue to a holder who Net Exercises a number of Warrant Shares computed using the following
formula: 
  

			
	 	  	 Y (A - B)

	X =	  	        A

  
 Where 
  

			
		
	 X =
	 	The number of Warrant Shares to be issued to the holder.
		
	 Y =
	 	The number of Warrant Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being cancelled (at the date of such
calculation).
		
	 A =
	 	The fair market value of one (1) Warrant Share (at the date of such calculation).
		
	 B =
	 	The Warrant Price (as adjusted to the date of such calculation (the “Determination Date”)).

  

 -2- 

 For purposes of this Section 2, the fair market value of a Warrant Share shall mean: 
  

	 	(i)	If traded on a securities exchange, the Nasdaq National Market or Nasdaq SmallCap Market, the fair market value of the Common Stock shall be deemed to be the average of the closing
prices of the Common Stock on such exchange or market over the 10 trading days immediately prior to the Determination Date; 

  

	 	(ii)	If traded on the Nasdaq Stock Market (other than the Nasdaq National Market or Nasdaq SmallCap Market) or other over-the-counter system, the fair market value of the Common Stock
shall be deemed to be the average of the closing bid prices of the Common Stock over the 10 trading days immediately prior to the Determination Date; and 

  

	 	(iii)	If there is no public market for the Common Stock, the fair market value shall be the price per Warrant Share that the Company could obtain from a willing buyer for Warrant Shares
sold by the Company from authorized but unissued Warrant Shares, as such prices shall be determined in good faith by the Company’s Board of Directors. 

  
 In the event that this Warrant is exercised pursuant to this Section 2 in connection with the consummation of the
Company’s sale of its Common Stock or other securities pursuant to a registration statement under the Securities Act of 1933, as amended (other than a registration statement relating either to sale of securities to employees of the Company
pursuant to its stock option, stock purchase or similar plan or a Rule 145 transaction) (“Public Offering”), the fair market value per Warrant Share shall be the per share offering price to the public of the Public Offering.

  
 3. Stock Fully Paid; Reservation of
Shares. All Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all taxes, liens and charges with
respect to the issue thereof. During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. 
  
 4. Adjustment of Warrant Price and Number of Shares. The number and kind of securities purchasable upon the exercise of this
Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
  
 (a) Fundamental Transaction. If, at any time while this Warrant is outstanding, (A) the Company effects any merger or consolidation of the Company
with or into another entity, (B) the Company effects any sale of all or substantially all of its assets in one or a 

  

 -3- 

 
series of related transactions, (C) any tender offer or exchange offer (whether by the Company or another person or entity) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (D) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property (in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the holder shall have the right to receive, for
each Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the holder, (a) upon exercise of this Warrant, the number of shares of Common Stock of the successor or
acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable upon or as a result of such reorganization, reclassification, merger,
consolidation or disposition of assets by a holder of the number of Shares for which this Warrant is exercisable immediately prior to such event or (b) if the Company is acquired in an all cash transaction, cash equal to the value of this Warrant as
determined in accordance with the Black Scholes Pricing Model (as hereafter defined). For purposes of any such exercise, the determination of the Warrant Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Warrant Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental
Transaction shall issue to the holder a new warrant consistent with the foregoing provisions and evidencing the holder’s right to exercise such warrant into Alternate Consideration; provided that this Warrant shall have been cancelled or
amended to the extent such cancellation or amendment is necessary so that such new warrant does not unjustly or disproportionately enrich the holder of the new warrant relative to a holder of the number of Shares for which this Warrant is
exercisable immediately prior to such event. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 4(a)
and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. For purposes hereof, “Black Scholes Pricing Model” means the value
determined using the Black Scholes pricing model assuming that the Warrant had been assumed by the acquiring company and determining volatility on an implied basis using pricing information for trading of options in the stock of the acquiring
company as of the date of determination or, if no such pricing information is available, determining volatility on an historical basis for the 12-month period prior to the date of determination. 
  

 -4- 

 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains
outstanding and unexpired shall subdivide or combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a
subdivision or the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination. 
  
 (c) Stock Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and
unexpired shall pay a dividend or make a distribution to all of its stockholders with respect to its Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the date of determination of stockholders entitled to
receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock
outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution. If the Company at any time while this
Warrant is outstanding and unexpired shall pay a dividend or make a distribution to all of its stockholders with respect to its Common Stock, any (i) cash (excluding cash dividends payable solely out of earnings or earned surplus of the Company) or
(ii) additional stock, rights, warrants or other securities or property (other than cash) by way of dividend, other than additional shares of Common Stock, then and in each such case the holder, on the exercise hereof as provided in Section 2, shall
be entitled to receive the amount of stock, rights, warrants and property (including cash in the case referred to in subdivision (i) above) which the holder would hold on the date of such exercise if on the date of such action (or the record date
therefor) the holder had been the holder of record of the number of shares of Common Stock for which this Warrant is exercisable as provided in Section 2 and had thereafter, during the period from the date thereof to and including the date of such
exercise, retained such shares and all such other or additional stock, rights, warrants and property (including cash in the case referred to in subdivision (i) above) receivable by the holder as aforesaid during such period. 
  
 (d) Adjustment of Number of Shares. Upon each adjustment in the
Warrant Price, the number of Shares purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction,
the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
  
 5. Notice of Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder
shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief executive officer, chief financial officer or any vice president setting forth, in reasonable detail, the event requiring the adjustment, the
amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause 

  

 -5- 

 
copies of such certificate to be mailed (without regard to Section 14 hereof, by first class mail, postage prepaid) to the holder of this Warrant.

  
 6. Fractional Shares. No fractional
shares of Common Stock will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Common Stock on the date of exercise as
determined pursuant to the penultimate sentence of Section 2(b) above. 
  
 7. Optional Redemption. 
  
 (a) Optional Redemption. At any time during the Optional Redemption Period, the Company shall have the right on one occasion only to redeem this Warrant in whole or in part as provided herein by payment of the Optional Redemption
Price pursuant to this Section 7 on the Optional Redemption Date, so long as the following conditions precedent are satisfied: 
  
 (i) a Registration Statement covering the resale by the Holder of shares of Common Stock issuable upon the exercise of this Warrant is effective and
available for use by the Holder; 
  
 (ii) on at least 15 Trading
Days in the period of 20 consecutive Trading Days ending on and including a Trading Day that is not more than five Trading Days prior to the date the Company gives the Optional Redemption Notice in substantially the form set forth as Exhibit A-3,
the VWAP of the Common Stock shall have been at least 200 percent of the Warrant Price in effect on such Trading Day; and 
  
 (iii) on the date the Optional Redemption Notice is given, the Company has funds available to pay the Optional Redemption Price on the Optional Redemption
Date, 
  
 (b) Procedures for Exercising Optional
Redemption. In order to exercise its right of redemption under this Section 7, the Company shall give an Optional Redemption Notice to the Holder not less than ten Trading Days or more than twenty Trading Days prior to the Optional Redemption
Date, stating that: 
  
 (i) the Company is
exercising its right to redeem this Warrant in accordance with this Section 7; 
  
 (ii) the number of shares of Common Stock subject to this Warrant to be redeemed; 
  
 (iii) the amount of the Optional Redemption Price payable on
the Optional Redemption Date; 
  
 (iv) the
Optional Redemption Date; and 
  

 -6- 

 (v) that all of the conditions of this Section 7 entitling the Company to call this
Warrant for redemption have been met. 
  
 On the Optional Redemption Date (or such
later date as the Holder surrenders this Warrant to the Company) the Company shall pay to or upon the order of the Holder, by wire transfer of immediately available funds to such account as shall be specified for such purpose by the Holder.

  
 (c) The Company shall not be entitled to give the Optional
Redemption Notice or to redeem any portion of this Warrant with respect to which the Holder has given a Notice of Exercise on or prior to the date the Company gives the Optional Redemption Notice. Notwithstanding the giving of the Optional
Redemption Notice, the Holder shall be entitled to exercise all or any portion of this Warrant, at any time until the Optional Redemption Date, in accordance with the terms of this Warrant, by giving a notice of exercise. On and after the Optional
Redemption Date, the Holder shall have no further rights except to receive, upon surrender of this agreement the Optional Redemption Price. 
  
 (d) In order that the Company shall not discriminate among the Holder and the holders of the Other Warrants, the Company agrees that the redemption of
this Warrants pursuant to this Section 7 shall be made at the same time as a redemption by the Company of the Other Warrants and that such redemption shall be made pro rata based on the number of shares of Common Stock issuable upon the exercise of
this Warrant and the Other Warrants outstanding on the date the Company gives the Optional Redemption Notice. In order that the Company not discriminate among the Holders and the holders of the Other Warrants, the Company agrees that it shall not
redeem any of the other Warrants pursuant to the provisions thereof similar to this Section 7(c) unless the Company simultaneously redeems this Warrant in accordance with this Section 7(c). 
  
 (e) As used in this Section 7, the following terms have the definitions
ascribed to them below: 
  

	 	(i)	“Optional Redemption Date” means, with respect to the redemption of this Warrant pursuant to Section 7, the Trading Day, selected by the Company in accordance with Section
7, on which this Warrant is to be redeemed. 

  

	 	(ii)	“Optional Redemption Period” means the period that commences on February 15, 2006 and ends on August 15, 2010. 

  

	 	(iii)	“Optional Redemption Price” means $0.001. 

  

	 	(iv)	“Other Purchase Agreements” means the several Purchase Agreements, dated as of August 11, 2005, by and between the Company and the respective initial holders of the Other
Warrants. 

  

	 	(iv)	 “Other Warrants” means the several Warrants to purchase Common Stock of the Company issued by the Company pursuant to the Other Purchase 

  

 -7- 

	 	 
Agreements, or any such Warrant issued upon transfer thereof or in replacement of any such Warrant that is lost, stolen, destroyed or mutilated, as the same
may be amended or supplemented in accordance with the terms hereof and thereof. 

  

	 	(v)	“Principal Market” means at any time Nasdaq or such other U.S. market or exchange which is the principal market on which the Common Stock is then listed for trading.

  

	 	(vi)	“Trading Day” means at any time a day on which the Principal Market is open for the general trading of securities. 

  

	 	(vii)	“VWAP” of any security on any Trading Day means the volume-weighted average price of such security on such Trading Day on the Principal Market, as reported by Bloomberg
Financial, L.P., based on a Trading Day from 9:30 a.m., Eastern Time, to 4:00 p.m., Eastern Time, using the AQR Function, for such Trading Day. 

  

8. Compliance with Securities Act; Disposition of Warrant or Shares of Common Stock. 
  
 (a) Compliance with Securities Act. The holder of this Warrant, by
acceptance hereof, agrees that such holder will not offer, sell or otherwise dispose of this Warrant, or any Shares except under circumstances which will not result in a violation of the Act or any applicable state securities laws. Upon exercise of
this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the Shares so purchased are not
being acquired with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant and all Shares issued upon exercise of this Warrant
(unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with a legend in substantially the following form: 
  
 “THE WARRANT AND THE SHARES OF COMMON STOCK REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND
MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER OR
HYPOTHECATION IS IN COMPLIANCE THEREWITH.” 
  

 -8- 

 Said legend shall be removed by the Company, upon the request of a holder, at such time as the
restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows: 
  
 (1) The holder is aware of the Company’s business
affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account and not with a view to, or
for the resale in connection with, any “distribution” thereof in violation of the Act. 
  
 (2) The holder understands that this Warrant has not been registered under the Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of the holder’s investment as expressed herein. 
  
 (3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified
under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. 
  
 (4) The holder is an “accredited investor” as such
term is defined in Rule 501 of Regulation D promulgated under the Act. 
  
 (b) Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or Shares, the holder
hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence reasonably satisfactory to the Company, to the effect that
such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not under the
Act certificates for this Warrant or the Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and
reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than fifteen (15) days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise dispose of this
Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 8(b) that the opinion of counsel for the holder or other evidence is not reasonably
satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the foregoing, this Warrant or such Shares may, as to such federal laws, be offered, sold or
otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a reasonable assurance 

  

 -9- 

 
that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the Shares thus transferred (except a transfer
pursuant to Rule 144) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure
compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
  
 (c) Applicability of Restrictions. Neither any restrictions of any legend described in this Warrant nor the requirements of Section 8(b) above
shall apply to any transfer or grant of a security interest in, this Warrant (or the shares of Common Stock obtainable upon exercise thereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a member of the
holder if the holder is a limited liability company, (ii) to a partnership of which the holder is a partner or a limited liability company of which the holder is a member, or (iii) to any affiliate of the holder if the holder is a corporation;
provided, however, in any such transfer, if applicable, the transferee shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
  
 9. Rights as Stockholders. No holder of this Warrant,
as such, shall be entitled to vote or receive dividends or be deemed the holder of Common Stock or any other securities which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to
confer upon the holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive notice of
meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 
  
 10. Registration Rights. The Company grants
registration rights to the holder of this Warrant for any shares of Common Stock of the Company obtained upon exercise hereof as set forth in the Securities Purchase Agreement. 
  
 11. Mergers. The Company shall provide the holder of this Warrant with at least twenty (20)
days’ written notice prior to the closing thereof of the terms and conditions of any of the following transactions: (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s property or
business or (ii) its merger into or consolidation with any other corporation in which the Company is not the surviving entity (other than a wholly-owned subsidiary of the Company) or (iii) any transaction (including a merger or other reorganization)
or series of related transactions, in which more than 50% of the voting power of the Company is disposed of; provided, however, that any SEC filing made by the Company on Edgar related to any of the transactions referenced in clauses (i), (ii) or
(iii) shall serve as notice for the purpose of this Section 11. 
  

 -10- 

 12. Representations and Warranties. The Company represents and warrants to the
holder of this Warrant as follows: 
  
 (a) This Warrant has been
duly authorized and executed by the Company and is a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency, moratorium, reorganization and the
relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies (regardless of whether enforcement is sought in equity or at law); 
  
 (b) The Shares have been duly authorized and reserved for issuance by the
Company and, when issued in accordance with the terms hereof will be validly issued, fully paid and non-assessable; 
  
 (c) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof
will not be, inconsistent with the Company’s certificate of incorporation or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or
contravene any provision of, or constitute a default under, any material indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the
registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings
will be effected by the time required thereby; and 
  
 (d) There
are no actions, suits, audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, will have
a material adverse effect on the ability of the Company to perform its obligations under this Warrant. 
  
 13. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement of the same is sought. 
  
 14. Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be mailed (A) if within
the United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile or electronic mail, or (B) if delivered from outside the United States, by International Federal
Express (or other recognized international express courier) or facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail, three business days after so mailed, (ii) if delivered by nationally recognized
overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express (or other recognized international express courier), two business days after so mailed, or (iv) if delivered by facsimile or electronic mail,
upon electronic confirmation of receipt and shall be delivered as addressed as follows: 
  
 if to the Company, to: 
  
 Xenogen Corporation 
 860 Atlantic Avenue 
 Alameda, CA 94501 
 Phone: (510) 291-6100 
 Attn: Jason Brady 
  

 -11- 

 with a copy to: 
  

Heller Ehrman LLP 
 333 Bush Street

 San Francisco, CA 94104 
 Phone: (415) 772-6000 
 Attn: Karen Dempsey 
  

if to the holder, at its address as shown on the books of the Company. 
  
 15. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the
Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and all of the obligations of the Company relating to the Shares issuable upon the exercise or conversion of this Warrant shall survive the
exercise, conversion and termination of this Warrant and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the holder hereof. 
  
 16. Lost Warrants or Stock Certificates. The Company covenants to the holder hereof that, upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably
satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost,
stolen, destroyed or mutilated Warrant or stock certificate. 
  
 17. Descriptive Headings. The descriptive headings of the several paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be
construed as to its fair meaning without regard to which party drafted this Warrant. 
  
 18. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed
by, the laws of the State of New York. 
  
 19.
Survival of Representations, Warranties and Agreements. All representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof)
or the termination or expiration of rights hereunder. All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. 
  

 -12- 

 20. Remedies. In case any one or more of the covenants and agreements contained in
this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights either by suit in equity and/or by
action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. 
  
 21. No Impairment of Rights. The Company will not, by
amendment of its certificate of incorporation or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment. 
  
 22. Severability. Whenever possible, each provision of this Warrant shall be interpreted in such a manner as to be valid, legal and
enforceable under all applicable laws and regulations. If, however, any provision of this Warrant shall be invalid, illegal or unenforceable under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified
to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed to be so modified, it shall be invalid, illegal or unenforceable only to the extent of such invalidity, illegality or limitation on
enforceability without affecting the remaining provisions of this Warrant or the validity, legality or enforceability of such provision in any other jurisdiction. 
  
 23. Entire Agreement; Modification. This Warrant constitutes the entire agreement between the parties
pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter; provided, however, that any
non-disclosure agreement signed by the holder of this Warrant shall survive the execution of this Warrant. 
  
 [Remainder of page intentionally left blank] 
  

 -13- 

 IN WITNESS WHEREOF, the parties have executed this Warrant as of the date first written above.

  

			
	 XENOGEN CORPORATION

		
	 By:
	 	 
	 Name:
	 	William A. Albright, Jr.
	 Title:
	 	Senior Vice President and Chief
Financial Officer
		
	 	 	                    Address: 860 Atlantic Avenue
	 	 	                    Alameda, CA 94501

  

 -14- 

 Exhibit A-1 
  
 Notice of Exercise 
  

	1.	The undersigned hereby: 

  

	 	 ̈	elects to purchase              shares of Common Stock of the Company pursuant to the terms of the attached
Warrant, and tenders herewith payment of the purchase price of such shares in full. 

  

	 	 ̈	elects to exercise its issuance rights pursuant to Section 2(b) of the attached Warrant with respect to
             shares of Common Stock of the Company. 

  

	2.	Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified below: 

 

			
		
	 	 	 
	 	 	(Name)
		
	 	 	 
		
	 	 	 
		
	 	 	 
	 	 	(Address)

  

	3.	The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with,
the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws. 

  

			
	
	 
	(Signature)
		
	Dated:	 	 
	 	 	 

 Exhibit A-2 
  
 Notice of Exercise 
  

	1.	Contingent upon and effective immediately prior to the closing (“Closing”) of the Company’s public offering contemplated by the Registration Statement filed
with the Securities and Exchange Commission filed on                     , the undersigned hereby: 

  

	 	 ̈	elects to purchase              shares of Common Stock of the Company (or such lesser number of shares as may be
sold on behalf of the undersigned at the Closing) pursuant to the terms of the attached Warrant. 

  

	2.	Please deliver to the custodian for the selling stockholders a stock certificate representing such             
shares. 

  

	3.	The undersigned has instructed the custodian for the selling stockholders to deliver to the Company $            
or, if less, the net proceeds due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price for such shares, the undersigned agrees to deliver the difference to the Company prior
to the Closing. 

  

	
	
	 
	(Name)
	
	 
	
	 
	
	 
	(Address)

  
 Dated:
                                        

 Exhibit A-3 
  
 Xenogen Corporation 
  
 Optional Redemption Notice 
  
 TO:
                                        

     (Name of Holder) 
  
 1. Pursuant to the terms of the Warrant to purchase Common Stock (the “Warrant”), Xenogen Corporation, a Delaware corporation (the
“Company”), the Company hereby notifies the above-named Holder that the Company is exercising its right to redeem the Warrant in accordance with Section 7 of the Warrant as set forth below: 
  
 (i) The number of shares of Common Stock of the Company
issuable pursuant to the Warrant to be redeemed is                     . 
  
 (ii) The Optional Redemption Price is
                    . 
  
 (iii) The Optional Redemption Date is
                    . 
  
 2. All of the conditions of Section 6 of the Warrant for this redemption have been satisfied. 
  
 3. Capitalized terms used herein and not otherwise defined herein have the
respective meanings provided in the Warrant. 
  

											
	 Date
	 	 _____________________
	 	 	 	Xenogen Corporation
					
	 	 	 	 	 	 	 By: 
	 	 
						
	 	 	 	 	 	 	 Title:Form of Securities Purchase Agreement

 Exhibit 10.1 
  
 SECURITIES PURCHASE AGREEMENT 
  

Xenogen Corporation 
 860 Atlantic Avenue 
 Alameda, CA 94501 
  
 Ladies & Gentlemen: 
  
 The
undersigned,                              (the “Investor”), hereby confirms its agreement
with you as follows: 
  
 1. This Securities Purchase Agreement (the
“Agreement”) is made as of August 11, 2005 between Xenogen Corporation, a Delaware corporation (the “Company”), and the Investor. 
  
 2. The Company has authorized the sale and issuance of up to 5,154,639 shares (the “Shares”) of common stock of the Company, $0.001 par value per share
(the “Common Stock”), and Warrants (the “Warrants”) to purchase up to 1,546,392 shares of Common Stock at an exercise price of $2.91 per share (the “Warrant Shares”) to certain investors in a private placement (the
“Offering”). 
  
 3. The Company and the Investor agree that the Investor
will purchase from the Company and the Company will issue and sell to the Investor                      Shares and a Warrant to
purchase                      Warrant Shares, for a purchase price of $3.29 per share, or an aggregate purchase price of
$                    , pursuant to the Terms and Conditions for Purchase of Shares and Warrants attached hereto as Annex I and
incorporated herein by reference as if fully set forth herein (the “Terms and Conditions”). This Securities Purchase Agreement, together with the Terms and Conditions which are incorporated herein by reference as if fully set forth herein,
may hereinafter be referred to as the “Agreement.” Unless otherwise requested by the Investor, the Warrant and certificates representing the Shares purchased by the Investor will be registered in the Investor’s name and address as set
forth below. The Warrant shall have the rights, preferences, privileges and restrictions as set forth in the form of Warrant attached as Exhibit B. 
  
 4. The Investor represents that, except as set forth below, (a) it has had no position, office or other material relationship within the past three years with the Company
or persons known to it to be affiliates of the Company, (b) neither it, nor any group of which it is a member or to which it is related, beneficially owns (including the right to acquire or vote) any securities of the Company and (c) it has no
direct or indirect affiliation or association with any NASD member as of the date hereof. Exceptions: 
  
  
                                       
                                        
                                        
                                        
                                        
                  . 
 (If no exceptions, write
“none.” If left blank, response will be deemed to be “none.”) 
  
 5. Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose. By executing this Agreement, the Investor acknowledges that the Company may use the information in
paragraph 4 above and the name and address information below in preparation of the Registration Statement (as defined in Annex 1). This Agreement may be executed in separate counterparts, each of which shall be deemed to be an original and all of
which taken together shall constitute one and the same instrument. 
  

									
	 AGREED AND ACCEPTED:
	 	 	 	 	 	 
	Xenogen Corporation	 	 	 	 Investor:
	 	 
					
	 	 	 	 	 	 	 By:
	 	 
	 By:
	 	 David Carter
	 	 	 	 Print Name:
	 	 
	 Title:
	 	 Chairman and CEO
	 	 	 	 Title:
	 	 
					
	 	 	 	 	 	 	 Address:
	 	 
					
	 	 	 	 	 	 	 	 	 
					
	 	 	 	 	 	 	 Tax ID No.: 
	 	 
					
	 	 	 	 	 	 	 Contact name:
	 	 
					
	 	 	 	 	 	 	 Telephone:
	 	 
				
	 	 	 	 	 	 	Name in which shares should be registered (if different):
	 	 	 	 	 	 	 

  

 -1- 

 ANNEX I 
  

TERMS AND CONDITIONS FOR PURCHASE OF SHARES AND WARRANTS 
  

1. Authorization and Sale of the Shares and Warrants. Subject to these Terms and Conditions, the Company has authorized the sale of up to
5,154,639 Shares and Warrants to purchase up to 1,546,392 Warrant Shares. Subject to the other provisions contained herein, the Company reserves the right to increase or decrease this number. 
  
 2. Agreement to Sell and Purchase the Shares and Warrants; Subscription
Date. 
  
 2.1 At the Closing (as defined in
Section 3), the Company will sell to the Investor, and the Investor will purchase from the Company, upon the terms and conditions hereinafter set forth, the number of Shares and a Warrant to purchase the number of Warrant Shares, each as set forth
in Section 3 of the Securities Purchase Agreement to which these Terms and Conditions are attached at the purchase price set forth thereon. 
  
 2.2 The Company may enter into the same form of Securities Purchase Agreement, including these Terms and Conditions, with other investors
(the “Other Investors”) and expects to complete sales of Shares and Warrants to them. (The Investor and the Other Investors are hereinafter sometimes collectively referred to as the “Investors,” and the Securities Purchase
Agreement to which these Terms and Conditions are attached and the Securities Purchase Agreements (including attached Terms and Conditions) executed by the Other Investors are hereinafter sometimes collectively referred to as the
“Agreements.”) The Company may accept executed Agreements from Investors for the purchase of Shares and Warrants commencing upon the date on which the Company provides the Investors with the proposed purchase price per Share and concluding
upon the date (the “Subscription Date”) on which the Company has (i) executed Agreements with Investors for the purchase of at least
[                    ] Shares and Warrants to purchase at least
[                    ] Warrant Shares, and (ii) notified Thomas Weisel Partners LLC, in its capacity as placement agent for this transaction
(the “Placement Agent”), that it is no longer accepting additional Agreements from Investors for the purchase of Shares and Warrants. The Company may not enter into any Agreements after the Subscription Date. 
  
 2.3 The obligations of each Investor under any Agreement are
several and not joint with the obligations of any Other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Agreement. Nothing contained herein, and no action taken by any
Investor hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated hereby, provided that such obligations or the transactions contemplated hereby may be modified, amended or waived in accordance with Section 9 below. Each Investor shall be entitled to independently
protect and enforce its rights, including without limitation the rights arising out of this Agreement (provided, that such rights may be modified, amended or waived in accordance with Section 9 below), and it shall not be necessary for any Other
Investor to be joined as an additional party in any proceeding for such purpose. 
  
 3. Delivery of the Shares and Warrants at Closing. The completion of the purchase and sale of the Shares and Warrants (the “Closing”) shall occur on August 15, 2005 (the “Closing Date”), at
the offices of the Company’s counsel. At the Closing, the Company shall deliver to the Investor one or more stock certificates representing the number of Shares and a Warrant to purchase the number of Warrant Shares, each as set forth pursuant
to Section 3 of the Securities Purchase Agreement, each such certificate to be registered in the name of the Investor or, if so indicated on the signature page of the Securities Purchase Agreement, in the name of a nominee designated by the
Investor. 
  
 The Company’s obligation to issue and deliver
the Shares and Warrant to the Investor shall be subject to the following conditions, any one or more of which may be waived by the Company: (a) receipt 

  

 -2- 

 
by Heller Ehrman LLP (the “Escrow Agent”) of a certified or official bank check or wire transfer of funds in the full amount of the purchase price
for the Shares and Warrant being purchased hereunder as set forth in Section 3 of the Securities Purchase Agreement; (b) completion of the purchases and sales under the Agreements with the Other Investors; (c) receipt by the Company of a completed
Investor Questionnaire; and (d) the accuracy of the representations and warranties made by the Investors and the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing. 
  
 The Investor’s obligation to purchase the Shares and Warrant shall be
subject to the following conditions, any one or more of which may be waived by the Investor: (a) Investors shall have executed Agreements for the purchase of at least
[                    ] Shares and Warrants to purchase at least
[                    ] Warrant Shares (the “Minimum Purchase Amount”); (b) the representations and warranties of the Company set
forth herein shall be true and correct as of the Closing Date in all material respects (except for representations and warranties that speak as of a specific date, which representations and warranties shall be true and correct as of such date); and
(c) the Investor shall have received such documents as such Investor shall reasonably have requested, including, a standard opinion of the Company’s counsel as to the matters set forth in Section 4.2 and as to exemption from the registration
requirements of the Securities Act of 1933, as amended (the “Securities Act”), of the sale of the Shares and Warrants. 
  
 4. Representations, Warranties and Covenants of the Company. The Company hereby represents and warrants to, and covenants with, the Investor, as of
the date hereof and Closing Date, as follows: 
  
 4.1 Organization. The Company and each of its Subsidiaries (as defined in Rule 405 under the Securities Act) is duly organized and validly existing in good standing under the laws of the jurisdiction of its organization. Each of the
Company and its Subsidiaries has full power and authority to own, operate and occupy its properties and to conduct its business as presently conducted and as described in the documents filed by the Company under the Securities Exchange Act of 1934,
as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”), since the end of its most recently completed fiscal year through the date hereof, including, without limitation, its most recent report on Form 10-K
(the “Exchange Act Documents”) and, except for the state of Missouri, is registered or qualified to do business and in good standing in each jurisdiction in which the nature of the business conducted by it or the location of the properties
owned or leased by it requires such qualification and where the failure to be so qualified would have a material adverse effect upon the condition (financial or otherwise), earnings, business, properties or operations of the Company and its
Subsidiaries, considered as one enterprise (a “Material Adverse Effect”), and no proceeding has been instituted in any such jurisdiction, revoking, limiting or curtailing, or seeking to revoke, limit or curtail, such power and authority or
qualification. 
  
 4.2 Due Authorization and
Valid Issuance. The Company has all requisite power and authority to execute, deliver and perform its obligations under the Agreements and the Warrants, and the Agreements and the Warrants have been duly authorized and validly executed and
delivered by the Company and constitute legal, valid and binding agreements of the Company enforceable against the Company in accordance with their terms, except as rights to indemnity and contribution may be limited by state or federal securities
laws or the public policy underlying such laws, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and
except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). The Shares and the Warrant being purchased by the Investor hereunder and the
Warrant Shares issuable pursuant to the Warrant will, upon issuance and payment therefor pursuant to the terms hereof and thereof, be duly authorized, validly issued, fully-paid and nonassessable. 
  
 4.3 Non-Contravention. The execution and delivery of
the Agreements and the Warrants, the issuance and sale of the Shares and the Warrants under the Agreements and the Warrant 

  

 -3- 

 
Shares under the Warrant, the fulfillment of the terms of the Agreements and the Warrants and the consummation of the transactions contemplated thereby will
not (A) conflict with or constitute a violation of, or default (with the passage of time or otherwise) under, (i) any bond, debenture, note or other evidence of indebtedness, lease, contract, indenture, mortgage, deed of trust, loan agreement, joint
venture or other agreement or instrument to which the Company or any Subsidiary is a party or by which it or any of its Subsidiaries or their respective properties are bound, (ii) the charter or by-laws of the Company or any Subsidiary, or (iii) any
law, administrative regulation, ordinance or order of any court or governmental agency, arbitration panel or authority applicable to the Company or any Subsidiary or their respective properties, except in the case of clauses (i) and (iii) for any
such conflicts, violations or defaults which are not reasonably likely to have a Material Adverse Effect or (B) result in the creation or imposition of any lien, encumbrance, claim, security interest or restriction whatsoever upon any of the
material properties or assets of the Company or any Subsidiary or an acceleration of indebtedness pursuant to any obligation, agreement or condition contained in any bond, debenture, note or any other evidence of indebtedness or any material
indenture, mortgage, deed of trust or any other agreement or instrument to which the Company or any Subsidiary is a party or by which any of them is bound or to which any of the material property or assets of the Company or any Subsidiary is subject
except for any such creation or imposition which is not reasonably likely to have a Material Adverse Effect. No consent, approval, authorization or other order of, or registration, qualification or filing with, any regulatory body, administrative
agency, or other governmental body in the United States or any other person (including, without limitation, the stockholders of the Company) is required for the execution and delivery of the Agreements and the Warrants and the valid issuance and
sale of the Shares and Warrants to be sold pursuant to the Agreements, and the valid issuance of the Warrant Shares under the Warrant, other than such as have been made or obtained, and except for post-closing securities filings or notifications
required to be made under federal or state securities laws. 
  
 4.4 Capitalization. The capitalization of the Company as of March 31, 2005 is as set forth in the most recent applicable Exchange Act Documents, increased as set forth in the next sentence. The Company has not
issued any capital stock since that date other than pursuant to (i) employee benefit plans disclosed in the Exchange Act Documents, or (ii) outstanding warrants, options or other securities disclosed in the Exchange Act Documents. The Shares and
Warrants to be sold pursuant to the Agreements, and the Warrant Shares to be issued pursuant to the Warrant, have been duly authorized, and when issued and paid for in accordance with the terms of the Agreements and the Warrants, as the case may be,
will be duly and validly issued, fully paid and nonassessable. The outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state
securities laws, and were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. Except as set forth in or contemplated by the Exchange Act Documents, there are no outstanding rights (including,
without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, to obtain any unissued shares of capital stock or other equity interest from the Company or any Subsidiary, or any contract,
commitment, agreement, understanding or arrangement of any kind to which the Company is a party or of which the Company has knowledge and relating to the issuance or sale of any capital stock of the Company or any Subsidiary, any such convertible or
exchangeable securities or any such rights, warrants or options. Without limiting the foregoing, except as set forth in the Exchange Act Documents, no preemptive right, co-sale right, right of first refusal, registration right, or other similar
right exists with respect to the Shares, the Warrants or the Warrant Shares or the issuance and sale thereof. No further approval or authorization of any stockholder, the Board of Directors of the Company or others is required for the issuance and
sale of the Shares, the Warrants and the Warrant Shares, including under Nasdaq rules. The Company owns the entire equity interest in each of its Subsidiaries, free and clear of any pledge, lien, security interest, encumbrance, claim or equitable
interest, other than as described in the Exchange Act Documents. Except as disclosed in the Exchange Act Documents, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Common Stock to which the
Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 
  

 -4- 

 4.5 Legal Proceedings. There is no material legal or governmental proceeding
pending or, to the knowledge of the Company, threatened to which the Company or any Subsidiary is or may be a party or of which the business or property of the Company or any Subsidiary is subject that is not disclosed in the Exchange Act Documents
and which is required to be disclosed. 
  
 4.6
No Violations. Neither the Company nor any Subsidiary is (i) in violation of its charter, bylaws, or other organizational document, or (ii) in violation of any law, administrative regulation, ordinance or order of any court or governmental
agency, arbitration panel or authority applicable to the Company or any Subsidiary, which violation, individually or in the aggregate, would be reasonably likely to have a Material Adverse Effect, or (iii) in default (and there exists no condition
which, with the passage of time or otherwise, would constitute a default) in the performance of any bond, debenture, note or any other evidence of indebtedness in any indenture, mortgage, deed of trust or any other material agreement or instrument
to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or by which the properties of the Company or any Subsidiary are bound, which would be reasonably likely to have a Material Adverse Effect.

  
 4.7 Governmental Permits, Etc. With
the exception of the matters which are dealt with separately in Sections 4.1, 4.12, 4.13 and 4.14, each of the Company and its Subsidiaries has all necessary franchises, licenses, certificates and other authorizations from any foreign, federal,
state or local government or governmental agency, department, or body that are currently necessary for the operation of the business of the Company and its Subsidiaries as currently conducted and as described in the Exchange Act Documents except
where the failure to currently possess could not reasonably be expected to have a Material Adverse Effect. 
  
 4.8 Intellectual Property. Except as specifically disclosed in the Exchange Act Documents, to the best knowledge of the Company (i)
each of the Company and its Subsidiaries owns or possesses sufficient rights to conduct its business in the ordinary course, including, without limitation, rights to use all material patents, patent rights, industry standards, trademarks,
copyrights, licenses, inventions, trade secrets, trade names and know-how (collectively, “Intellectual Property”) described or referred to in the Exchange Act Documents as owned or possessed by it or that are necessary for the conduct of
its business as now conducted or as proposed to be conducted except where the failure to currently own or possess would not have a Material Adverse Effect and (ii) neither the Company nor any of its Subsidiaries is infringing, or has received any
notice of, or has any knowledge of, any asserted infringement by the Company or any of its Subsidiaries of, any rights of a third party with respect to any Intellectual Property that, individually or in the aggregate, would have a Material Adverse
Effect. 
  
 4.9 Financial Statements. (a)
The financial statements of the Company and the related notes contained in the Exchange Act Documents present fairly, in accordance with generally accepted accounting principles, the financial position of the Company and its Subsidiaries as of the
dates indicated, and the results of its operations and cash flows for the periods therein specified except that the unaudited interim financial statements were or are subject to normal and recurring year-end adjustments which will not be material in
amount. Such financial statements (including the related notes) have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods therein specified, except as may be disclosed in the
notes to such financial statements, or in the case of unaudited statements, as may be permitted by the Securities and Exchange Commission (“SEC”) on Form 10-Q under the Exchange Act and except as disclosed in the Exchange Act Documents.
The other financial information contained in the Exchange Act Documents has been prepared on a basis consistent with the financial statements of the Company. 
  

(b) Except as set forth in any Exchange Act Documents, there are no obligations of the Company to officers, directors, stockholders or
employees of the Company other than (i) for payment of salary for services rendered and for bonus payments; (ii) reimbursements for reasonable expenses incurred on behalf of the Company; (iii) for other standard employee benefits made generally
available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company); and (iv) obligations listed in the Company’s financial statements. 

  

 -5- 

 
Except as described above or in any Exchange Act Filings, none of the officers, directors or, to the best of the Company’s knowledge, key employees or
stockholders of the Company or any members of their immediate families, are indebted to the Company, individually or in the aggregate, in excess of $60,000 or have any direct or indirect ownership interest in any firm or corporation with which the
Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with the Company, other than passive investments in publicly traded companies (representing less than one percent (1%) of such
company) which may compete with the Company. Except as described above, no officer, director or stockholder, or any member of their immediate families, is, directly or indirectly, interested in any material contract with the Company and no
agreements, understandings or proposed transactions are contemplated between the Company and any such person. Except as set forth in any Exchange Act Documents, the Company is not a guarantor or indemnitor of any indebtedness of any other person,
firm or corporation. 
  
 4.10 No Material
Adverse Change. Except as disclosed in the Exchange Act Documents, since March 31, 2005, there has not been (i) any event which has had, or would be reasonably expected to have, a Material Adverse Effect; (ii) any obligation, direct or
contingent, that is material to the Company and its Subsidiaries considered as one enterprise, incurred by the Company, except obligations incurred in the ordinary course of business, (iii) any dividend or distribution of any kind declared, paid or
made on the capital stock of the Company or any of its Subsidiaries, or (iv) any loss or damage (whether or not insured) to the physical property of the Company or any of its Subsidiaries which has been sustained which has a Material Adverse Effect.

  
 4.11 Disclosure. The representations
and warranties of the Company contained in this Section 4 as of the date hereof and as of the Closing Date, do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. Except with respect to the material terms and conditions of the transaction contemplated by the Agreements and the Warrants, which shall be publicly
disclosed by the Company pursuant to Section 16 hereof, the Company confirms that neither it nor any person acting on its behalf has provided Investor with any information that the Company believes constitutes material, non-public information. The
Company understands and confirms that Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 
  
 4.12 NASDAQ Compliance. The Company’s Common Stock is registered pursuant to Section 12(g) of the Exchange Act and is listed
on The Nasdaq Stock Market, Inc. National Market (the “Nasdaq National Market”), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or
de-listing the Common Stock from the Nasdaq National Market, nor has the Company received any notification that the SEC or the National Association of Securities Dealers, Inc. (“NASD”) is contemplating terminating such registration or
listing. The Company is in compliance with all applicable Nasdaq maintenance requirements and corporate governance requirements for continuing listing on Nasdaq National Market. The issuance by the Company of the Shares, the Warrants, and the
Warrant Shares shall not have the effect of terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq National Market. 
  
 4.13 Reporting Status. The Company is eligible to use Form S-3 to register the Shares and Warrant
Shares to be offered for the account of the Investors. The following documents complied in all material respects with the SEC’s requirements as of their respective filing dates, and the information contained therein as of the date thereof did
not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances under which they were made not misleading: 
  

	 	(a)	the Annual Report on Form 10-K for the fiscal year ended December 31, 2004, filed by the Company with the SEC on March 21, 2005; 

  

 -6- 

	 	(b)	the Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, filed by the Company with the SEC on May 16, 2005; and 

  

	 	(c)	all other documents, if any, filed by the Company with the SEC during the one-year period preceding the date of this Agreement pursuant to the reporting requirements of the Exchange
Act. 

  
 4.14 Listing. The
Company shall comply with all requirements of the Nasdaq and SEC with respect to the issuance of the Shares; the Company shall submit to the Nasdaq National Market a Notification Form: Listing of Additional Shares related to the Shares and the
Warrant Shares. 
  
 4.15 No Manipulation of
Stock. The Company has not taken and will not, in violation of applicable law, take, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Common Stock to facilitate
the sale or resale of the Shares or the Warrant Shares. 
  
 4.16 Company not an “Investment Company”. The Company has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the “Investment Company Act”). To
the best knowledge of the Company, the Company is not, and immediately after receipt of payment for the Shares and Warrants will not be, an “investment company” or an entity “controlled” by an “investment company”
within the meaning of the Investment Company Act and shall conduct its business in a manner so that it will not become subject to the Investment Company Act. 
  

4.17 Foreign Corrupt Practices. Neither the Company, nor to the best knowledge of the Company, any executive officer or director
acting on behalf of the Company, has (i) directly or indirectly, used any corrupt funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 
  
 4.18 Accountants. To the Company’s knowledge Deloitte & Touche LLP, who the Company expects
will consent to the incorporation by reference of its report dated March 18, 2005 with respect to the consolidated financial statements of the Company included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004
into the Registration Statement (as defined below) and the prospectus which forms a part thereof, are independent accountants as required by the Securities Act and the rules and regulations promulgated thereunder. 
  
 4.19 Contracts. The contracts described in the
Exchange Act Documents that are material to the Company are in full force and effect on the date hereof, and neither the Company nor, to the Company’s knowledge, any other party to such contracts is in breach of or default under any of such
contracts which would have a Material Adverse Effect. The Company has filed with the SEC all contracts and agreements required to be filed by the Exchange Act. 
  
 4.20 Taxes. The Company has filed all necessary federal, state and foreign income and franchise tax
returns when due (or obtained appropriate extensions for filing) and has paid or accrued all taxes shown as due thereon, and the Company has no knowledge of a tax deficiency which has been or might be asserted or threatened against it which would
have a Material Adverse Effect. 
  
 4.21
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income taxes) which are required to be paid in connection with the sale and transfer of the Shares and the Warrant to be sold to the Investor hereunder will
be, or will have been, fully paid or provided for by they Company and all laws imposing such taxes will be or will have been fully complied with. Upon the 

  

 -7- 

 
issuance of the Warrants Shares pursuant to the Warrant all stock transfer or other taxes (other than income taxes) which are required to be paid in
connection therewith will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with. 
  
 4.22 Private Offering. Assuming the correctness of the representations and warranties of the
Investors set forth in Section 5 hereof, the offer and sale of Shares, the Warrants and the Warrant Shares is exempt from registration under the Securities Act. The Company has not distributed and will not distribute prior to the Closing Date any
offering material in connection with this Offering and sale of the Shares, the Warrants and the Warrant Shares other than the documents of which this Agreement is a part or the Exchange Act Documents. The Company has not in the past nor will it
hereafter take any action independent of the placement agent to sell, offer for sale or solicit offers to buy any securities of the Company which would bring the offer, issuance or sale of the Shares, the Warrants or the Warrant Shares within the
provisions of Section 5 of the Securities Act, unless such offer, issuance or sale was or shall be within the exemptions of Section 4 of the Securities Act. Neither the Company nor any person acting on behalf of the Company has offered or
sold any of the Shares, the Warrants or the Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Shares, the Warrants and the Warrant Shares for sale only to the Investors and certain other
“accredited investors” within the meaning of Rule 501 under the Securities Act. 
  
 4.23 Controls and Procedures. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are
applicable to it as of the Closing Date. The Company has established and maintains an effective system of internal control over financial reporting (as such term is defined in the Exchange Act ) regarding the reliability of financial reporting and
preparation of financial statements for external purposes in accordance with GAAP and includes policies and procedures that (i) pertain to maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
dispositions of the assets of the issuer; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the issuer are being
made only in accordance with authorizations of management and directors of the issuer; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the issuer’s assets that
could have a material adverse effect on the financial statements. The Company has established and maintains disclosure controls and procedures (as defined in Exchange Act) that are effective in ensuring that information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, including, without limitation, controls and procedures
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal
financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls
and procedures and presented in the applicable Exchange Act Documents their conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by such Exchange Act Documents based on such evaluation.
Since the last such evaluation date, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting, and no significant deficiencies or material weaknesses in internal controls over financial reporting, or other factors that could significantly affect the Company’s internal control over financial reporting, have been
identified. 
  
 4.24 Transactions With
Affiliates. Except as disclosed in the Exchange Act Documents, none of the officers or directors of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and
directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer or 

  

 -8- 

 
director or, to the knowledge of the Company, any entity in which any officer or director has a substantial interest or is an officer, director, trustee or
partner. Notwithstanding the foregoing, Investor acknowledges that certain affiliates of the Company may participate in the transactions contemplated by this Agreement. 
  
 4.25 No Registration Rights. Except as set forth in the Exchange Act Documents and other than the
registration rights granted to the Investors in Section 7 of this Agreement, no person has the right, which right has not been waived, to require the Company or any Subsidiary to register any securities for sale under the Securities Act by reason of
the filing of the Registration Statement with the SEC or the issuance and sale of the Shares, the Warrants or the Warrant Shares. 
  
 5. Representations, Warranties and Covenants of the Investor. 
  
 5.1 The Investor represents and warrants to, and covenants with, the Company that: (i) (A) the Investor is
an “accredited investor” as defined in Regulation D under the Securities Act and the Investor is also knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares
presenting an investment decision like that involved in the purchase of the Shares and the Warrant, including investments in securities issued by the Company and investments in comparable companies, and has requested, received, reviewed and
considered all information it deemed relevant in making an informed decision to purchase the Shares and the Warrant and (B) the Company has made available to the Investor, prior to the date hereof, the opportunity to ask questions of and receive
complete and correct answers from representatives of the Company concerning the terms and conditions of the Shares and the Warrant and to obtain any additional information relating to the financial condition and business of the Company (provided
that any investigation conducted by the Investor shall not affect its right to rely on the representations and warranties of the Company contained herein) and the Investor has such knowledge and experience in financial and business matters that the
Investor is capable of evaluating the merits and risks of the investment in the Shares and the Warrant; (ii) the Investor is acquiring the number of Shares and the Warrant to purchase the number of Warrant Shares, each as set forth in Section 3 of
the Securities Purchase Agreement in the ordinary course of its business and for its own account and with no present intention of distributing any of such Shares, Warrant or Warrant Shares (other than pursuant to the Registration Statement or any
exemption from the registration requirements of the Securities Act) or any arrangement or understanding with any other persons regarding the distribution of such Shares, Warrant or Warrant Shares; (iii) the Investor will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares and the Warrant except in compliance with the Securities Act, applicable state securities laws
and the respective rules and regulations promulgated thereunder; (iv) the Investor has answered all questions on the Investor Questionnaire for use in preparation of the Registration Statement and the answers thereto are true, correct and complete
in all material respects as of the date hereof and will be true, correct and complete as of the Closing Date and the Filing Date; (v) the Investor will notify the Company of any change in any of such information until such time as the Investor has
sold all of its Shares and Warrant Shares or until the Company is no longer required to keep the Registration Statement effective; and (vi) the Investor has, in connection with its decision to purchase the number of Shares and the Warrant to
purchase the number of Warrant Shares, each as set forth in Section 3 of the Securities Purchase Agreement, relied only upon the Exchange Act Documents, the information provided to it pursuant to clause (i)(B) of this Section 5.1 and the
representations and warranties of the Company contained herein. The Investor understands that its acquisition of the Shares and the Warrant has not been registered under the Securities Act or registered or qualified under any state securities law in
reliance on specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide nature of the Investor’s investment intent as expressed herein. Subject to compliance with the Securities Act, applicable securities
laws and the respective rules and regulations promulgated thereunder, nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Shares, Warrant or Warrant Shares for any period of time. The Investor has
completed or caused to be completed and delivered to the Company the Investor Questionnaire, which questionnaire is true, correct and complete in all material respects. 
  

 -9- 

 5.2 The Investor acknowledges, represents and agrees that no action has been or will be
taken in any jurisdiction outside the United States by the Company that would permit an offering of the Shares, Warrant or Warrant Shares, or possession or distribution of offering materials in connection with the issue of the Shares, Warrant or
Warrant Shares, in any jurisdiction outside the United States where legal action by the Company for that purpose is required. Each Investor outside the United States will comply with all applicable laws and regulations in each foreign jurisdiction
in which it purchases, offers, sells or delivers the Shares, Warrant or Warrant Shares or has in its possession or distributes any offering material, in all cases at its own expense. 
  
 5.3 The Investor hereby covenants with the Company not to make any sale of the Shares, Warrant or Warrant
Shares without complying with the provisions of this Agreement and, if applicable, without complying with any prospectus delivery requirement then applicable to it, and the Investor acknowledges that the Warrant and certificates evidencing the
Shares will be imprinted with a legend that prohibits their transfer except in accordance therewith. The Investor acknowledges that there may occasionally be times when the Company determines that it must suspend the use of the Prospectus forming a
part of the Registration Statement, as set forth in Section 7.2(c). 
  
 5.4 The Investor further represents and warrants to, and covenants with, the Company that (i) the Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions
contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (ii) this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in
accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability
may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except as the indemnification agreements of the Investors herein may be legally unenforceable.

  
 5.5 Neither the Investor nor any person
acting on its behalf or at its direction has engaged in any purchase or sale of Common Stock (including without limitation any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-1(h)
under the Exchange Act) during the 5 trading days immediately preceding the date of this Agreement. Investor will not use any of the restricted Shares acquired pursuant to this Agreement, or the Warrant Shares acquired pursuant to the Warrant, to
cover any short position in the Common Stock of the Company if doing so would be in violation of applicable securities laws and otherwise will comply with federal securities laws in the holding and sale of the Shares, Warrant and Warrant Shares.

  
 5.6 The Investor understands that nothing in
the Exchange Act Documents, this Agreement, the Warrant or any other materials presented to the Investor in connection with the purchase and sale of the Shares and the Warrant constitutes legal, tax or investment advice. The Investor has consulted
such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares and the Warrant. 
  
 5.7 The Company acknowledges and agrees that Investor does not make or has not made any representations or
warranties with respect to the transactions contemplated hereby other than those specifically set forth in Sections 4 and 5 of this Agreement, Sections 5 and 16(a) of Annex 1 of this Agreement, or in the Investor Questionnaire. 
  
 6. Survival of Representations, Warranties and Agreements.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investor herein shall survive the execution of this Agreement, the delivery to the Investor
of the Shares and the Warrant being purchased and the payment therefor until the expiration date of the Company’s obligation to keep the Registration Statement effective pursuant to Section 7.1(c). 
  

 -10- 

 7. Registration of the Shares and Warrant Shares; Compliance with the Securities Act. 

 
 7.1 Registration Procedures and Other Matters. The
Company shall: 
  
 (a) subject to receipt of
necessary information from the Investor after prompt request from the Company to the Investor to provide such information, prepare and file with the SEC, within 30 calendar days after the Closing Date (the “Filing Date”), a registration
statement on Form S-3 (the “Registration Statement”) to enable the resale of the Shares and the Warrant Shares by the Investors from time to time through the automated quotation system of the Nasdaq National Market or in
privately-negotiated transactions; 
  
 (b)
subject to receipt of necessary information from the Investor after prompt request from the Company to the Investors to provide such information, use its reasonable commercial efforts to cause the Registration Statement to become effective on or
prior to the 90th calendar day after the Closing Date (the “Required Effective Date”). However, so long as
the Company filed the Registration Statement by the Filing Date, if the Registration Statement receives Commission review, then the Required Effective Date will be the 120th calendar day after the Closing Date; 
  
 (c) use its reasonable commercial efforts to prepare and file with the SEC such amendments and supplements to the Registration Statement
and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement current, effective and free from any material misstatement or omission to state a material fact for a period not exceeding, with respect to each
Investor’s Shares and Warrant Shares, the earlier of (i) the second anniversary of the Closing Date, (ii) the date on which the Investor may sell all Shares and Warrant Shares then held by the Investor without restriction by the volume
limitations of Rule 144(k) of the Securities Act, or (iii) such time as all Shares, and Warrant Shares issuable pursuant to the Warrant, purchased by such Investor in this Offering have been sold pursuant to a registration statement; 
  
 (d) comply with any prospectus publication requirement then
applicable to it and furnish to the Investor with respect to the Shares and Warrant Shares registered under the Registration Statement such number of copies of the Registration Statement, Prospectuses and Preliminary Prospectuses in conformity with
the requirements of the Securities Act and such other documents as the Investor may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Shares and Warrant Shares by the Investor; provided, however,
that the obligation of the Company to deliver copies of Prospectuses or Preliminary Prospectuses to the Investor shall be subject to the receipt by the Company of reasonable assurances from the Investor that the Investor will comply with the
applicable provisions of the Securities Act and of such other securities or blue sky laws as may be applicable in connection with any use of such Prospectuses or Preliminary Prospectuses; 
  
 (e) file documents required of the Company for normal blue
sky clearance in states specified in writing by the Investor and use its reasonable commercial efforts to maintain such blue sky qualifications during the period the Company is required to maintain the effectiveness of the Registration Statement
pursuant to Section 7.1(c); provided, however, that the Company shall not be required to qualify to do business or consent to service of process in any jurisdiction in which it is not now so qualified or has not so consented; 
  
 (f) bear all expenses in connection with the procedures in
paragraph (a) through (e) of this Section 7.1 (other than underwriting discounts or commissions, brokers’ fees and similar selling expenses, and any other fees or expenses incurred by the Investor, including attorney fees of the Investor) and
the registration of the Shares and Warrant Shares pursuant to the Registration Statement; 
  

 -11- 

 (g) advise the Investor, promptly after it shall receive notice or obtain knowledge of
the issuance of any stop order by the SEC delaying or suspending the effectiveness of the Registration Statement or of the initiation or threat of any proceeding for that purpose; and it will promptly use its reasonable commercial efforts to prevent
the issuance of any stop order or to obtain its withdrawal at the earliest possible moment if such stop order should be issued; and 
  
 (h) provide a “Plan of Distribution” section of the Registration Statement in the form attached hereto as Exhibit A.

  
 Notwithstanding anything to the contrary herein, the
Registration Statement shall cover only the Shares and Warrant Shares. In no event at any time before the expiration of the earlier of (i) 120 days after the date of this Securities Purchase Agreement or (ii) the effective date of the Registration
Statement with respect to the Shares and Warrant Shares shall the Company publicly announce or file any other registration statement, other than registrations on Form S-8, without the prior written consent of a majority in interest of the
Investors. 
  
 The Company understands that the Investor
disclaims being an underwriter, but if the SEC deems the Investor to be an underwriter the Company shall not be relieved of any obligations it has hereunder; provided, however that if the Company receives notification from the SEC that
the Investor is deemed an underwriter, then the period by which the Company is obligated to submit an acceleration request to the SEC shall be extended to the earlier of (i) the 90th day after such SEC notification, or (ii) 120 days after the
initial filing of the Registration Statement with the SEC. 
  
 7.2 Transfer of Shares and Warrant Shares After Registration; Suspension. 
  
 (a) The Investor agrees that it will not effect any disposition of the Shares or Warrant Shares or its right to purchase the Shares or
Warrant Shares that would constitute a sale within the meaning of the Securities Act except as contemplated in the Registration Statement referred to in Section 7.1 and as described below or as otherwise permitted by law, and that it will promptly
notify the Company of any changes in the information set forth in the Registration Statement regarding the Investor or its plan of distribution. 
  
 (b) Except in the event that paragraph (c) below applies, the Company shall (i) if deemed necessary by the Company, prepare and file from
time to time with the SEC a post-effective amendment to the Registration Statement or a supplement to the related Prospectus or a supplement or amendment to any document incorporated therein by reference or file any other required document so that
such Registration Statement will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and so that, as thereafter delivered to
purchasers of the Shares or Warrant Shares being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading; (ii) provide the Investor copies of any documents filed pursuant to Section 7.2(b)(i) as the Investor may reasonably request; and (iii) inform each Investor that the Company has
complied with its obligations in Section 7.2(b)(i) (or that, if the Company has filed a post-effective amendment to the Registration Statement which has not yet been declared effective, the Company will notify the Investor to that effect, will use
its reasonable commercial efforts to secure the effectiveness of such post-effective amendment as promptly as possible and will promptly notify the Investor pursuant to Section 7.2(b)(i) hereof when the amendment has become effective). 

 
 (c) Subject to paragraph (d) below, in the event (i) of
any request by the SEC or any other federal or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to a Registration Statement or related Prospectus or for additional
information; (ii) of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any proceedings for that purpose; (iii) of the receipt
by the Company of any notification with respect to the 

  

 -12- 

 
suspension of the qualification or exemption from qualification of any of the Shares or Warrant Shares for sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; or (iv) of any event or circumstance which, upon the advice of its counsel, necessitates the making of any changes in the Registration Statement or Prospectus, or any document incorporated or deemed to
be incorporated therein by reference, so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or any omission to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, and that in the case of the Prospectus, it will not contain any untrue statement of a material fact or any omission to state a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; then the Company shall deliver a certificate in writing to the Investor (the “Suspension Notice”) to the effect of the foregoing and, upon receipt of
such Suspension Notice, the Investor will refrain from selling any Shares or Warrant Shares pursuant to the Registration Statement (a “Suspension”) until the Investor’s receipt of copies of a supplemented or amended Prospectus
prepared and filed by the Company, or until it is advised in writing by the Company that the current Prospectus may be used, and has received copies of any additional or supplemental filings that are incorporated or deemed incorporated by reference
in any such Prospectus. In the event of any Suspension, the Company will use its reasonable commercial efforts to cause the use of the Prospectus so suspended to be resumed as soon as reasonably practicable within 20 business days after the delivery
of a Suspension Notice to the Investor. In addition to and without limiting any other remedies (including, without limitation, at law or at equity) available to the Investor, the Investor shall be entitled to specific performance in the event that
the Company fails to comply with the provisions of this Section 7.2(c). 
  
 (d) Notwithstanding the foregoing paragraphs of this Section 7.2, the Investor shall not be prohibited from selling Shares and Warrant
Shares under the Registration Statement as a result of Suspensions on more than two occasions of not more than 30 days each in any twelve month period, unless, in the good faith judgment of the Company’s Board of Directors, upon the written
opinion of counsel of the Company, the sale of Shares and Warrant Shares under the Registration Statement in reliance on this paragraph 7.2(d) would be reasonably likely to cause a violation of the Securities Act or the Exchange Act and result in
liability to the Company. 
  
 (e) Provided that a
Suspension is not then in effect, the Investor may sell Shares and Warrant Shares under the Registration Statement, provided that it complies with any prospectus delivery requirement then applicable to it. Upon receipt of a request therefor, the
Company has agreed to provide an adequate number of current Prospectuses to the Investor and to supply copies to any other parties requiring such Prospectuses. 
  

7.3 Indemnification. For the purpose of this Section 7.3: 
  
 (i) the term “Selling Stockholder” means the Investor and any affiliate of such Investor;

  
 (ii) the term “Registration
Statement” shall include the Prospectus in the form first filed with the SEC pursuant to Rule 424(b) of the Securities Act or filed as part of the Registration Statement at the time of effectiveness if no Rule 424(b) filing is required, and any
exhibit, supplement or amendment included in or relating to the Registration Statement referred to in Section 7.1; and 
  
 (iii) the term “Untrue Statement” means any untrue statement or alleged untrue statement, or any omission or alleged omission to
state in the Registration Statement a material fact required to be stated therein or necessary to make the statements therein not misleading. 
  
 (a) The Company agrees to indemnify and hold harmless each Selling Stockholder from and against any losses, claims, damages, liabilities,
or expenses to which such Selling Stockholder may become subject (under the Securities Act or otherwise) insofar as such losses, claims, damages, liabilities or expenses (or actions or proceedings in respect thereof) arise out of, or are based upon
(i) any breach of the representations or warranties of the Company contained herein or failure to 

  

 -13- 

 
comply with the covenants and agreements of the Company contained herein, (ii) any Untrue Statement, or (iii) any failure by the Company to fulfill any
undertaking included in the Registration Statement as amended or supplemented from time to time, and the Company will reimburse such Selling Stockholder for any reasonable legal or other expenses reasonably incurred in investigating, defending or
preparing to defend any such action, proceeding or claim, or preparing to defend any such action, proceeding or claim, provided, however, that the Company shall not be liable in any such case to the extent that such loss, claim, damage
or liability arises out of, or is based upon, an Untrue Statement made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Selling Stockholder specifically for use in preparation of the
Registration Statement, as amended or supplemented from time to time (including, without limitation, information set forth in the Investor Questionnaire as of its date), or the failure of such Selling Stockholder to comply with its covenants and
agreements contained in Section 7.2 hereof respecting sale of the Shares or Warrant Shares or any statement or omission in any Prospectus that is corrected in any subsequent Prospectus that was published by the Company, if applicable, and delivered
to the Selling Stockholder prior to the pertinent sale or sales by the Selling Stockholder. The Company shall reimburse each Selling Stockholder for the indemnifiable amounts provided for herein on demand as such expenses are incurred. 

 
 (b) The Investor agrees to indemnify and hold harmless
the Company (and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company) from and against any losses,
claims, damages or liabilities to which the Company (or any such officer, director or controlling person) may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings
in respect thereof) arise out of, or are based upon, (i) any failure of the Investor to comply with the covenants and agreements contained in Section 7.2 hereof respecting sale of the Shares and Warrant Shares, or (ii) any Untrue Statement if such
Untrue Statement was made in reliance upon and in conformity with written information furnished by or on behalf of the Investor specifically for use in preparation of the Registration Statement, as amended or supplemented from time to time
(including, without limitation, information set forth in the Investor Questionnaire as of its date), and the Investor will reimburse the Company (or such officer, director or controlling person), as the case may be, for any legal or other expenses
reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim. The Investor shall reimburse the Company or such officer, director or controlling person, as the case may be, for the indemnifiable amounts
provided for herein on demand as such expenses are incurred. Notwithstanding the foregoing, the Investor’s aggregate obligation to indemnify the Company and such officers, directors and controlling persons shall be limited to the net amount
received by the Investor from the sale of the Shares or Warrant Shares, as the case may be. 
  
 (c) Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which indemnity
is to be sought against an indemnifying person pursuant to this Section 7.3, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, but the omission to so notify the indemnifying
person will not relieve it from any liability which it may have to any indemnified person under this Section 7.3 (except to the extent that such omission materially and adversely affects the indemnifying person’s ability to defend such action)
or from any liability otherwise than under this Section 7.3. Subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person, the indemnifying person shall be entitled to participate therein, and,
to the extent that it shall elect by written notice delivered to the indemnified person promptly after receiving the aforesaid notice from such indemnified person, shall be entitled to assume the defense thereof, with counsel reasonably satisfactory
to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying person shall not be liable to such indemnified person for any legal expenses
subsequently incurred by such indemnified person in connection with the defense thereof, provided, however, that if there exists or shall exist a conflict of interest that would make it inappropriate, in the opinion of counsel to the
indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled to retain its own counsel at the expense of such
indemnifying person; 

  

 -14- 

 
provided, however, that no indemnifying person shall be responsible for the fees and expenses of more than one separate counsel (together with appropriate
local counsel) for all indemnified parties. In no event shall any indemnifying person be liable in respect of any amounts paid in settlement of any action unless the indemnifying person shall have approved the terms of such settlement;
provided that such consent shall not be unreasonably withheld or delayed. No indemnifying person shall, without the prior written consent of the indemnified person, effect any settlement of any pending or threatened proceeding in respect of
which any indemnified person is or could have been a party and indemnification could have been sought hereunder by such indemnified person, unless such settlement includes an unconditional release of such indemnified person from all liability on
claims that are the subject matter of such proceeding. 
  
 (d) If the indemnification provided for in this Section 7.3 is unavailable to or insufficient to hold harmless an indemnified person under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions or
proceedings in respect thereof) referred to therein, then each indemnifying person shall contribute to the amount paid or payable by such indemnified person as a result of such losses, claims, damages or liabilities (or actions in respect thereof)
in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and the Investor, as well as any other Selling Shareholders under such Registration Statement on the other in connection with the statements or
omissions or other matters which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault shall be determined by reference to, among other
things, in the case of an Untrue Statement, whether the Untrue Statement relates to information supplied by the Company on the one hand or an Investor or other Selling Shareholder on the other and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such Untrue Statement. The Company and the Investor agree that it would not be just and equitable if contribution pursuant to this subsection (d) were determined by pro rata allocation (even if
the Investor and other Selling Shareholders were treated as one entity for such purpose) or by any other method of allocation which does not take into account the equitable considerations referred to above in this subsection (d). The amount paid or
payable by an indemnified person as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such
indemnified person in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), the Investor shall not be required to contribute any amount in excess of the amount by which the net
amount received by the Investor from the sale of the Shares or Warrant Shares, as the case may be to which such loss relates exceeds the amount of any damages which such Investor has otherwise been required to pay by reason of such Untrue Statement.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Investor’s obligations
in this subsection to contribute shall be in proportion to its sale of Shares and Warrant Shares to which such loss relates and shall not be joint with any other Selling Shareholders. 
  
 (e) The parties to this Agreement hereby acknowledge that they are sophisticated business persons who were
represented by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions of this Section 7.3, and are fully informed regarding said provisions. They further acknowledge that the provisions of this
Section 7.3 fairly allocate the risks in light of the ability of the parties to investigate the Company and its business in order to assure that adequate disclosure is made in the Registration Statement as required by the Securities Act and the
Exchange Act. The parties are advised that federal or state public policy as interpreted by the courts in certain jurisdictions may be contrary to certain of the provisions of this Section 7.3, and the parties hereto hereby expressly waive and
relinquish any right or ability to assert such public policy as a defense to a claim under this Section 7.3 and further agree not to attempt to assert any such defense. 
  
 7.4 Termination of Conditions and Obligations. The conditions precedent imposed by Section 5 or this
Section 7 upon the transferability of the Shares and Warrant Shares shall cease and terminate as to any particular number of the Shares or Warrant Shares, as the case may be, when such Shares or Warrant Shares shall have been effectively registered
under the Securities Act and sold or 

  

 -15- 

 
otherwise disposed of in accordance with the intended method of disposition set forth in the Registration Statement covering such Shares and Warrant Shares
or at such time as an opinion of counsel reasonably satisfactory to the Company shall have been rendered to the effect that such conditions are not necessary in order to comply with the Securities Act. 
  
 7.5 Information Available. So long as the
Registration Statement is effective covering the resale of Shares and Warrant Shares owned by the Investor, upon the reasonable request of the Investor, the Company will furnish to the Investor: 
  
 (a) as soon as practicable after it is available, one copy
of (i) its Annual Report to Stockholders (which Annual Report shall contain financial statements audited in accordance with generally accepted accounting principles by a national firm of certified public accountants), (ii) its Annual Report on Form
10-K and (iii) its Quarterly Reports on Form 10-Q (the foregoing, in each case, excluding exhibits); 
  
 (b) all exhibits excluded by the parenthetical to subparagraph (a) of this Section 7.5 as filed with the SEC and all other information
that is made available to shareholders; and 
  
 (c) an adequate number of copies of the Prospectuses to supply to any other party requiring such Prospectuses; and upon the reasonable request of the Investor, the President or the Principal Financial Officer of the Company (or an
appropriate designee thereof) will meet with the Investor or a representative thereof at the Company’s headquarters to discuss all information relevant for disclosure in the Registration Statement covering the Shares and Warrant Shares and will
otherwise cooperate with any Investor conducting an investigation for the purpose of reducing or eliminating such Investor’s exposure to liability under the Securities Act, including the reasonable production of information at the
Company’s headquarters; provided, that the Company shall not be required to disclose any confidential information to or meet at its headquarters with any Investor until and unless the Investor shall have entered into a confidentiality agreement
in form and substance reasonably satisfactory to the Company with the Company with respect thereto. 
  
 7.6 Legend; Restrictions on Transfer. The Warrant and certificate or certificates for the Shares (and any securities issued in
respect of or exchange for the Shares or Warrant) shall be subject to a legend or legends restricting transfer under the Securities Act and referring to restrictions on transfer herein, such legend to be substantially as follows: 
  
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE
SECURITIES, SUCH OFFER, SALE OR TRANSFER OR HYPOTHECATION IS IN COMPLIANCE THEREWITH. 
  
 The Company and the Investor acknowledge and agree that the Investor may, as permitted by law, from time to time pledge pursuant to a bona fide margin agreement or grant a security interest in some or all of the Shares, Warrant and Warrant
Shares and, if required under the terms of such arrangement, Investor may, as permitted by law, transfer pledged or secured Shares, Warrant and Warrant Shares to the pledgees or secured parties. So long as Investor is not an affiliate of the
Company, such a pledge or transfer would not be subject to approval or consent of the Company, provided that, upon the request of the Company, a legal opinion of legal counsel to the pledgee, secured party or pledgor shall be obtained. At the
Investor’s expense, so long as the Shares and Warrant are subject to the legend required by this Section 7.6, the Company will use its reasonable commercial efforts to execute and deliver such 

  

 -16- 

 
reasonable documentation as a pledgee or secured party of Shares and Warrant may reasonably request in connection with a pledge or transfer of the Shares and
Warrant including such amendments or supplements to the Registration Statement and Prospectus as may be reasonably required. The foregoing does not affect Investor’s obligations pursuant to Section 7.2(a). 
  
 The Investor expressly agrees that any sale by the Investor of Shares and
Warrant Shares pursuant to the Registration Statement shall be sold in a manner described under the caption “Plan of Distribution” in such Registration Statement and, if then required to do so, the Investor will deliver a copy of the
Prospectus contained in the Registration Statement to the purchaser or purchasers, directly or through the Investor’s broker, in connection with such sale, in each case in compliance with the requirements of the Securities Act and Exchange Act
applicable to such sale. The Investor further agrees that the Shares and Warrant Shares will only be sold while the Registration Statement is effective, unless another exemption from registration is available. On the basis of, and subject to,
compliance by the Investor with the foregoing covenants, upon the earlier of (i) the effectiveness of the Registration Statement, and (ii) Rule 144(k) becoming available with respect thereto, the Company shall as soon as practicable (but not later
than five business days after surrender of the legended certificates to the Company and notice of such surrender has been provided pursuant to Section 8(b) below) cause certificates evidencing the Shares and Warrant Shares previously issued to be
replaced with certificates which do not bear the restrictive legends specified above in this Section 7.6, and all Shares and Warrant Shares subsequently issued shall not bear the restrictive legend specified above in this Section 7.6. The Investor
acknowledges that the removal of the restrictive legends from certificates representing Shares and Warrant Shares as provided in this Section 7.6 is predicated upon the Company’s reliance on the Investor’s compliance with its covenants in
this Section 7.6. 
  
 7.7 Liquidated
Damages. The Company and Investor agree that Investor will suffer damages if the Company fails to fulfill its obligations pursuant to Section 7.1 and 7.2 hereof and that it would not be possible to ascertain the extent of such damages with
precision. Accordingly, the Company hereby agrees to pay liquidated damages (“Liquidated Damages”) to Investor under the following circumstances: (a) if the Registration Statement is not filed by the Company on or prior to 30 calendar days
after the Closing Date (such an event, a “Filing Default”); (b) if the Registration Statement is not declared effective by the SEC on or prior to 90 calendar days or, subject to the filing of the Registration Statement by the Filing Date,
in the event that the Registration Statement receives SEC review, 120 calendar days after the Closing Date (such an event, an “Effectiveness Default”); or (c) if the Registration Statement (after its effectiveness date) ceases to be
effective and available to Investor for any continuous period that exceeds 30 calendar days or for one or more period that exceeds in the aggregate 60 calendar days in any 12-month period (such an event, a “Suspension Default” and together
with a Filing Default and an Effectiveness Default, a “Registration Default”). In the event of a Registration Default, the Company shall as Liquidated Damages pay to Investor, for each 30 calendar day period of a Registration Default, an
amount in cash equal to 1% of the aggregate purchase price paid by Investor pursuant to this Agreement up to a maximum of 10% of the aggregate purchase price of the Shares and Warrants, provided that Liquidation Damages in respect of a Suspension
Default shall not be payable in relation to any Shares or Warrant Shares not owned by the Investor at the time of the Suspension Default. The Company shall pay the Liquidated Damages as follows: (i) in connection with a Filing Default, on the
31st business day after the Closing Date, and each 30th calendar day thereafter until the Registration Statement is
filed with the SEC; (ii) in connection with an Effectiveness Default, on the 90th calendar day (or, in the event that the Registration Statement receives SEC review, the 120th calendar day) after the Closing Date and each 30th calendar day
thereafter until the Registration Statement is declared effective by the SEC; or (iii) in connection with a Suspension Default, on either (x) the 31st consecutive day of any Suspension or (y) the 61st calendar day (in
the aggregate) of any Suspensions in any 12-month period, and each 30th calendar day thereafter until the Suspension
is terminated in accordance with Section 7.2. Notwithstanding the foregoing, the Company shall have no liability for Liquidated Damages to any Investor who is not named in an effective Registration Statement as a result of any action or inaction of
such Investor. The Liquidated Damages payable herein shall apply on a pro rata basis for any portion of a 30-day period of a Registration Default. 
  

 -17- 

 8. Notices. All notices, requests, consents and other communications hereunder shall be in
writing, shall be mailed (A) if within the United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile or electronic mail, or (B) if delivered from outside the
United States, by International Federal Express (or other recognized international express courier) or facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail, three business days after so mailed, (ii) if
delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express (or other recognized international express courier), two business days after so mailed, or (iv) if delivered
by facsimile or electronic mail, upon electronic confirmation of receipt and shall be delivered as addressed as follows: 
  

	 	(a)	if to the Company, to: 

  
 Xenogen Corporation 
 860 Atlantic Avenue

 Alameda, CA 94501 
 Phone:
(510) 291-6100 
 Attn: Jason Brady 
  

	 	(b)	with a copy to: 

  
 Heller Ehrman LLP 
 333 Bush Street

 San Francisco, CA 94104 
 Phone: (415) 772-6000 
 Attn: Karen Dempsey 
  

	 	(c)	if to the Investor, at its address on the signature page hereto, or at such other address or addresses as may have been furnished to the Company in writing.

  
 Notwithstanding anything in this Agreement to the contrary, (a)
the Company may deliver any documents, information or notices required to be delivered to an Investor under this Agreement by email, in any recognized electronic format, including Portable Document Format (PDF) or Microsoft Word document format, and
(b) with respect to any documents, exhibits, filings, furnishings or other submissions (other than any Registration Statement, Prospectus, or Preliminary Prospectus pursuant to Section 7 of this Agreement) publicly available on the SEC’s EDGAR
system (each, an “EDGAR Filing”), such EDGAR Filing shall be deemed furnished by the Company to such Investor, in each case as of the date first publicly available on the EDGAR system. 
  
 9. Changes. This Agreement may be modified, amended or waived only
pursuant to a written instrument signed by the Company and (a) Investors holding a majority of the Shares issued and sold in the Offering, provided that such modification, amendment or waiver is made with respect to all Agreements and does
not adversely affect the Investor without adversely affecting all Investors in a similar manner; or (b) the Investor. 
  
 10. Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed
to be part of this Agreement. 
  
 11. Severability. In case
any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

  

 -18- 

 12. Governing Law. This Agreement shall be governed by, and construed in accordance with, the
internal laws of the State of New York, without giving effect to the principles of conflicts of law. 
  
 13. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when
taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 
  
 14. Entire Agreement. This Agreement and the Warrant constitute the entire agreement between the parties hereto and
supersedes any prior understandings or agreements concerning the purchase and sale of the Shares and the Warrant and the resale registration of the Shares and Warrant Shares; provided, however, that any non-disclosure agreement signed by Investor
shall survive the execution of this Agreement. 
  
 15. Rule
144. The Company covenants that it will timely file the reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder (or, if the Company is not required to file such
reports, it will, upon the request of any Investor holding Shares purchased hereunder, or Warrant Shares purchased under any Warrant, made after the first anniversary of the Closing Date, make publicly available such information as necessary to
permit sales pursuant to Rule 144 under the Securities Act), and it will take such further action as any such Investor may reasonably request, all to the extent required from time to time to enable such Investor to sell such Shares and Warrant
Shares without registration under the Securities Act within the limitation of the exemptions provided by (a) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or (b) any similar rule or regulation hereafter adopted by
the SEC. Upon the request of the Investor, the Company will deliver to such holder a written statement as to whether it has complied with such information and requirements. 
  
 16. Confidential Information. The Company shall within one business day of the Closing Date issue a press release
disclosing any information provided by the Company or any person acting on its behalf that the Company believes constitutes material and non-public information. The Company shall timely file with the SEC a Form 8-K disclosing the material terms of
the transactions contemplated hereby (including at least the number of Shares and Warrants sold and proceeds therefrom). The Company shall not publicly disclose the name of Investor or any beneficial owner of Shares or Warrants held by Investor, or
include the name of Investor or such beneficial owner in any filing with the SEC or any state and federal regulatory agency or the Nasdaq (other than the filing of the Agreements with the SEC pursuant to the Exchange Act), without the prior written
consent of Investor, except to the extent such disclosure is required by law, regulation or Nasdaq regulations. 
  
 17. No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 
  
 18. Knowledge. The term “knowledge” in this Agreement shall mean the knowledge of the directors and officers of the Company and the
phrase “to the best of the Company’s knowledge” in this Agreement shall mean the knowledge of the directors and officers of the Company after due inquiry. 
  

 -19-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]